StemCell Therapy

OXNARD, California and TEL AVIV, Israel, July 11, 2017 /PRNewswire/ CURE Pharmaceutical (OTCQB: CURR), (CURE), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company and Therapix Biosciences (NASDAQ: Ltd. (Nasdaq: TRPX), (Therapix), a specialty clinical-stage pharmaceutical company dedicated to the development of cannabinoid-based drugs headquartered in Israel, announced today that they signed a memorandum of understanding (MOU) to enter into a research collaboration with Israels largest and leading private medical services center, Assuta Medical Centers, Ltd., (Assuta). The Companies will collaborate to advance, research, develop and commercialize potential therapeutic products in the fields of personalized medicine and cannabinoids.

As CURE focuses on targeting unmet needs in traditional pharmaceutical markets that could be disrupted by cannabinoid-based options, we are continuously looking to help bring new therapeutic cannabinoid-based products to market and further efforts toward the creation of personalized medicine, said Robert Davidson, CEO of CURE Pharmaceutical. Our new collaboration with Therapix and Assuta, two leading companies in Israel, a Country that is at the forefront of cannabinoid-based research in the world, is the perfect place to start the development of these products.

CURE is the ideal partner for us to enter this promising and cutting-edge personalized cannabinoid-based therapeutics; this deal has all the signs of a fruitful venture.

As agreed to in the MOU, the Companies intend to formalize the pooling of professional, scientific, financial resources and expertise, in order to benefit from each of its respective advantages and capabilities to develop new therapeutic products in the fields of personalized medicine and cannabinoids. Specifically, CURE and Therapix will provide support and expertise in the development of pharmaceutical products, while Assuta will support the early research and development of potential projects through its research and facilities.

Assuta is happy to enter into the MOU with CURE and Therapix, and I am confident that the parties cooperation will be a successful one, with many other projects to follow. This new collaboration is yet another step Assuta is taking in the innovation world, and one of many steps to be taken by Assuta in the field of biopharma.

About CURE Pharmaceutical

Headquartered in Oxnard, California, CURE Pharmaceutical (OTC:CURE) is a fully integrated specialty pharmaceutical/bioscience company that leverages disruptive proprietary drug delivery technologies for a broad range of molecules serving the biopharmaceutical, veterinarian, medical foods and pharmaceutical cannabis markets. CURE develops its patented and proprietary delivery system (CureFilm), the most advanced oral thin film on the market today, from its industry leading full service cGMP manufacturing facility. The Companys mission is to deliver proven drugs in a fast and efficient manner and to improve quality of life.

For more information about CURE Pharmaceutical, please visit its website at http://www.curepharmaceutical.com.

About Therapix Biosciences Ltd.

Therapix Biosciences Ltd. (Nasdaq: TRPX) is a specialty clinical-stage pharmaceutical company focused on developing technologies and therapeutics based on cannabinoid pharmaceuticals. The Companys clinical pipeline assets follow a de-risked 505(b)(2) regulatory pathway benefitting from Therapixs unique proprietary formulations based on repurposing an FDA approved synthetic cannabinoid (dronabinol). Therapixs lead compound, THX-TS01, is currently in Phase 2 clinical trials for Tourettes Syndrome and the Company intends to initiate a Phase 1 clinical study of THX-ULD01 for the treatment of Mild Cognitive Impairment, for which no FDA-approved therapies currently exist.

Please visit our website for more information at http://www.therapixbio.com.

About Assuta Medical Centers

Assuta Medical Centers (https://www.assuta.co.il/en/) is the largest private hospital network in Israel operating 8 hospitals and medical centers from north to south. Owned by Maccabi Healthcare, the second largest HMO in Israel, Assuta accounts for about 15% of the surgeries in Israel and takes care of the health of more than 1 million patients yearly. Assuta holds JCI quality accreditation with excellence and its service standards are ranked as top tier by the ministry of health.

Original press release:http://www.prnewswire.com/news-releases/cure-pharmaceuticaltherapix-biosciences-signs-mou-with-israels-assuta-medical-center-to-develop-first-in-class-therapeutic-products-in-fields-of-personalized-medicinecannabinoids-300486025.html

The most reliable, fact-based information on Therapix Biosciences found only on its Investor Dashboard.

Before this cannabis stock news is here, it's published to subscribers on 420 Investor.

The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. For questions contact us.

See original here:
CURE Pharmaceutical & Therapix Biosciences Signs MOU with Israel's Assuta Medical Center to Develop First-in ... - New Cannabis Ventures (blog)

This entry was posted on July 12, 2017 at 4:48 pm and is filed under Personalized Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |